Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on ...

In a new experimental study, scientists from Juntendo University in collaboration with researchers from the University of Tokyo have developed an adeno-associated virus (AAV) vector-mediated ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.

Adeno-associated virus vector containing an adenine base editor provides an effective strategy to treat hereditary hearing loss caused by the R75W mutation. Moreover, this gene editing technology ...

D Molecular Therapeutics, Inc.’s FDMT share price has surged by 5.88%, which has investors questioning if this is right time ...

NEW YORK – In cell and gene therapies, the genetic machinery is key to producing the proteins missing or dysregulated in a disease, but whether the therapeutic cassette reaches target cells and how ...

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

OXB Named Among UK’s Best Employers by Financial Times in 2025Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the ...